← All institutions

Nomura

110 reports

Reports from this institution

Nomura

Nomura: China shifts toward market stabilization; near-term Hong Kong stock performance depends on the extent of national team intervention

The central bank has launched a third round of the Securities, Funds and Insurance Companies Swap Facility and cut the interest rate on relending for share repurchases and stake increases. Nomura believes the policies show concern about sustained stock-market declines and leverage risks, but says their impact should not be overstated because both tools have been in place for two years.

Nomura

Nomura: Multinational drug and medical device companies’ China businesses rebound: New products and a low base drive growth, while procurement pressure persists

Third-quarter 2026 results compiled by Nomura show that pharmaceutical companies including Lilly and Novartis recorded rapid sales growth in China, while some medical device companies also returned to growth. However, currency movements, a low base and centralized procurement have made the extent of the recovery uneven.